Chemical structure of tetrahydrocannabinol
Find information on thousands of medical conditions and prescription drugs.

Dronabinol

Tetrahydrocannabinol, also known as THC, Δ9-THC, Δ9-tetrahydrocannabinol (delta-9-tetrahydrocannabinol), Δ¹-tetrahydrocannabinol (using an older numbering scheme), or dronabinol, is the main psychoactive substance found in the Cannabis plant. It was isolated by Raphael Mechoulam and Yechiel Gaoni from the Weizmann Institute in Rehovot, Israel in 1964. In pure form it is a glassy solid when cold and becomes viscous and sticky if warmed. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

THC has a very low solubility in water, but a good solubility in most organic solvents such as pure ethanol or hexane.

Pharmacology

Its pharmacological actions are the result of its binding to the cannabinoid receptor CB1, located in the brain. The presence of these specialized receptors in the brain implied to researchers that endogenous cannabinoids were manufactured by the body, so the search began for a substance normally manufactured in the brain that binds to these receptors, the so-called natural ligand or agonist, leading to the eventual discovery of anandamide and some related compounds. This story resembles the discovery of the endogenous opiates (endorphins, enkephalins, and dynorphin), after the realization that morphine and other opiates bound to specific receptors in the brain.

Effects include: relaxation, euphoria, altered space-time perception, alteration of visual, auditory, and olfactory senses, disorientation, fatigue and appetite stimulation. It also has anti-emetic (anti-nauseant) properties.

Toxicity

THC has a LD50 value of 1270 mg/kg (male rats) and 730 mg/kg (female rats) administered orally dissolved in sesame oil.

If this were scaled up to an adult human, the lethal dose would be between approximately 50 and 86 g for a 68 kg (150 lb) person. This would be equivalent to 1-1.8 kg of marijuana with a 5% THC content (roughly average) taken orally (much more if smoked). It is important to note, however, that toxicity studies in animal models do not necessarily correlate to human toxicity. THC receptor distribution in the rat CNS is different than that of humans, meaning that there is the significant possibility that toxicity in humans varies from the published animal LD50 studies. There has never been a documented fatality from marijuana or THC overdose.

Studies of the distribution of the cannabinoid receptors in the brain explain why THC's toxicity is so low (i.e., the LD50 of the compound is so large): parts of the brain that control vital functions such as respiration do not have many receptors, so they are relatively unaffected even by doses larger than could ever be ingested under any normal conditions.

Research

A number of studies indicate that THC may provide medical benefits for cancer and AIDS patients by increasing appetite and decreasing nausea, and by blocking the spread of some cancer-causing Herpes simplex viruses. It has been shown to assist some glaucoma patients by reducing pressure within the eye, and is used in the form of cannabis by a number of multiple sclerosis patients to relieve the spasms associated with their condition. Government studies indicate a variety of negative effects associated with constant, long-term use, including memory loss, depression and loss of motivation. The long-term effects of THC on humans have been disputed because its status as an illegal drug almost everywhere prevents free research into the subject. The issue has become deeply politicized.

Read more at Wikipedia.org


[List your site here Free!]


High Times for Medical Marijuana
From Family Pratice News, 8/15/00 by Sherry Boschert

One must weed through the politics to get anywhere near the science of medical marijuana.

The political trappings will be heavy this year as a class-action lawsuit brought by physicians against the federal government heads to court, and state ballots once again bring the question of medical marijuana before voters.

A 1996 California initiative legalized patients' cultivation or possession of marijuana for medical purposes with a physicians recommendation. But Office of National Drug Control Policy director Barry McCaffrey, Attorney General Janet Reno, and Secretary of Health Donna Shalala announced after the ballot that there are grounds for revoking the license of any physician recommending marijuana use.

Led by San Francisco dermatologist and AIDS specialist Dr. Marcus Conant, California physicians filed a lawsuit in 1997 against federal officials. The suit claims that the government was tying to restrict physician-patient dialogue protected by the First Amendment. The suit became a class action representing all California physicians treating patients with conditions that might benefit from marijuana use, and their affected patients.

Dr. Milton Estes recently sat across the table from government defense attorneys taking his deposition in the lawsuit. "It's unnerving to have to invoke the Fifth Amendment three times," Dr. Estes, an ob.gyn. on the faculty of the University of California, San Francisco, said at a meeting on cannabis therapy sponsored by the University of California, San Francisco.

In the interim, a U.S. district court judge has prohibited the government from threatening or prosecuting physicians, revoking their licenses, or excluding them from Medicare and Medicaid participation for recommending the medical use of marijuana, as long as they do not help patients obtain or cultivate the marijuana.

Any physician acting "in a professional, responsible manner should have nothing to fear under [California] state or federal law" when recommending medicinal marijuana, said Alice P. Mead, J.D., former legal counsel to the California Medical Association. She now counsels on medical affairs for a British pharmaceutical firm that is developing cannabis products.

The Drug Enforcement Agency classifies marijuana as a schedule I drug with "no currently accepted medical use." A synthetic version--dronabinol (Marinol)--recently was reclassified from schedule II to schedule III, meaning it has an accepted medical use and can be prescribed without a triplicate form, like any other medication.

A new peer-reviewed medical journal, the journal of Cannabis Therapeutics (Ha-worth Press, Binghamton, N.Y.), will join the fray with its first issue later this year. The editor will be Dr. Ethan B. Russo, a neurologist at the University of Washington and the University of Montana.

Voters in Colorado and Nevada will consider initiatives on ballots in November that would protect from prosecution patients who grow or possess marijuana with a doctor's recommendation. Nevada voters passed the initiative once, but the state constitution requires a second vote.

If passed, these states would join six others with comparable laws: Alaska, California, Hawaii, Maine, Oregon, and Washington. The District of Columbia passed a similar law that Congress overruled.

Lawmakers in nine more states considered comparable medical marijuana bills in the 1999-2000 legislative session without passing them: Arkansas, Iowa, Maryland, Massachusetts, Minnesota, New Hampshire, New York, Vermont, and Wyoming.

In 10 states, laws let doctors "prescribe" marijuana (the laws are largely symbolic because the federal government regulates prescribing): Arizona, Connecticut, Iowa, Louisiana, Montana, New Hampshire, Tennessee, Vermont, Virginia, and Wisconsin.

Fourteen states have laws to set up "therapeutic research and distribution programs" to facilitate medical marijuana research. So far none is running, according to the Marijuana Policy Project, Washington, D.C., a pro-marijuana advocacy group.

Legislative Initiatives on Medical Marijuana

* 6 states have laws that protect patients who possess and grow their own medical marijuana with a doctor's recommendation

* 14 states have laws that allow medical marijuana research and distribution programs, provided that the federal government cooperates

* 10 states and the District of Columbia have symbolic medical marijuana laws

* 15 states considered medical marijuana legislation during their 1999-2000 state legislative session

Source: Marijuana Policy Project

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Dronabinol
Home Contact Resources Exchange Links ebay